SEC Form 4 · accession 0001681643-26-000006
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Huda Y Zoghbi
Director
Period of report
Aug 10, 2026
Accepted (ET)
Aug 12, 2026 · 4:14 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2026 | M | 800 | $376.69 | A | 2,503 | D | |
| Common Stock | Aug 10, 2026 | S | 800 | $800.00 | D | 1,703 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $376.69 | Aug 10, 2026 | M | 800 | D | — | Jan 3, 2027 | Common Stock | 800 | 0 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.
- F2The stock option vested in three equal annual installments, commencing one year after the date of grant.